Physician profile
Charles E Lavalle
NPI 1477537975
$4,044.69
in general payments reported to CMS, 2019-2025
16 companies · $634 in 2025
The $634 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $157 · 2021: $328 · 2022: $567 · 2023: $804 · 2024: $773 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,839.70 | 2019-2025 | |
| Viiv Healthcare Company | $828.47 | 2020-2025 | Rukobia, Dovato, Apretude |
| Merck Sharp & Dohme LLC | $316.97 | 2019-2024 | Dificid, Zerbaxa, Delstrigo |
| Janssen Biotech, INC. | $269.27 | 2019-2023 | Symtuza |
| Insmed, INC. | $202.54 | 2019-2025 | Arikayce |
| Gilead Sciences, INC. | $171.88 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $151.16 | 2025 | Vowst, Zenpep |
| Janssen Products, LP | $97.56 | 2019 | |
| Mylan Institutional INC. | $46.81 | 2019 | |
| Emd Serono, INC. | $34.49 | 2024 | |
| Seqirus USA INC | $23.17 | 2025 | Fluad, Flucelvax |
| Sanofi Pasteur INC. | $13.46 | 2019 | |
| Pfizer INC. | $13.26 | 2022 | |
| Lilly USA, LLC | $12.40 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.18 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lavalle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.